ReviewInternational journal of obesity (2005)2026
Metabolism-disrupting compounds and metabolic health during the menopausal transition: a narrative review.
Review in International journal of obesity (2005), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Substantial evidence has linked endocrine-disrupting chemicals and other compounds to increased risk of elevated adiposity and adverse metabolic outcomes. Individuals may be particularly susceptible to these metabolism-disrupting chemicals or compounds (MDC) during sensitive periods. The menopausal transition is a sensitive window marked by increased risk of obesity, metabolic syndrome, and cardiovascular disease that continues into the postmenopausal period; however, evidence on modifiable risk factors, such as MDC exposure, in perimenopausal individuals is limited. Therefore, we conducted a review to understand the breadth of literature evaluating relationships of MDC exposure with metabolic health outcomes (e.g. body weight/composition, glycemic control, lipid profiles, blood pressure) across the menopausal transition. We identified 28 studies using data from four U.S.-based cohorts of midlife women. Overall, studies suggest that phthalates and other nonpersistent chemicals (7 studies), per- and polyfluoroalkyl substances (7 studies), persistent organic pollutants (3 studies), heavy metals (5 studies), and air pollutants (6 studies) were associated with increases in body fat, unfavorable adipokine profiles, adverse lipid profiles, and/or higher risk of type 2 diabetes and hypertension. Several studies identified differences by race/ethnicity. Although few studies stratified by menopause status, some results suggest that perimenopause may be a sensitive window of exposure to MDCs. Additional data are needed to identify susceptible windows of exposure during midlife, particularly in more diverse populations. Future research should consider examining cumulative exposure to multi-pollutant mixtures and identifying susceptible populations and mitigation strategies during this period.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.